Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51

Neelima Sanakkayala, Anna Sokolovska, Jatinder Gulani, Harm HogenEsch, Nammalwar Sriranganathan, Stephen M. Boyle, Gerhardt G. Schurig, Ramesh Vemulapalli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Brucella abortus strain RB51 is an attenuated rough mutant used as the live vaccine against bovine brucellosis in the United States and other countries. We previously reported the development of strain RB51 as a bacterial vaccine vector for inducing Th1-type immune responses against heterologous proteins. Because safety concerns may preclude the use of strain RB51-based recombinant live vaccines, we explored the ability of a gamma-irradiated recombinant RB51 strain to induce heterologous antigen-specific immune responses in BALB/c mice. Exposure of strain RB51G/LacZ expressing Escherichia coli β-galactosidase to a minimum of 300 kilorads of gamma radiation resulted in complete loss of replicative ability. These bacteria, however, remained metabolically active and continued to synthesize β-galactosidase. A single intraperitoneal inoculation of mice with 109 CFU equivalents of gamma-irradiated, but not heat-killed, RB51G/LacZ induced a β-galactosidase-specific Th1-type immune response. Though no obvious differences were detected in immune responses to B. abortus-specific antigens, mice vaccinated with gamma-irradiated, but not heat-killed, RB51G/LacZ developed significant protection against challenge with virulent B. abortus. In vitro experiments indicated that gamma-irradiated and heat-killed RB51G/LacZ induced maturation of dendritic cells; however, stimulation with gamma-irradiated bacteria resulted in more interleukin-12 secretion. These results suggest that recombinant RB51 strains exposed to an appropriate minimum dose of gamma radiation are unable to replicate but retain their ability to stimulate Th1 immune responses against the heterologous antigens and confer protection against B. abortus challenge in mice.

Original languageEnglish (US)
Pages (from-to)1429-1436
Number of pages8
JournalClinical and Diagnostic Laboratory Immunology
Volume12
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Brucella abortus
Galactosidases
Heterophile Antigens
Antigens
Hot Temperature
Gamma Rays
Bovine Brucellosis
Bacterial Vaccines
Bacteria
Gamma rays
Synthetic Vaccines
Interleukin-12
Dendritic Cells
Vaccines
Escherichia coli
Safety
Dosimetry
Proteins

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Clinical Biochemistry
  • Immunology

Cite this

Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51. / Sanakkayala, Neelima; Sokolovska, Anna; Gulani, Jatinder; HogenEsch, Harm; Sriranganathan, Nammalwar; Boyle, Stephen M.; Schurig, Gerhardt G.; Vemulapalli, Ramesh.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 12, No. 12, 12.2005, p. 1429-1436.

Research output: Contribution to journalArticle

Sanakkayala, N, Sokolovska, A, Gulani, J, HogenEsch, H, Sriranganathan, N, Boyle, SM, Schurig, GG & Vemulapalli, R 2005, 'Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51', Clinical and Diagnostic Laboratory Immunology, vol. 12, no. 12, pp. 1429-1436. https://doi.org/10.1128/CDLI.12.12.1429-1436.2005
Sanakkayala, Neelima ; Sokolovska, Anna ; Gulani, Jatinder ; HogenEsch, Harm ; Sriranganathan, Nammalwar ; Boyle, Stephen M. ; Schurig, Gerhardt G. ; Vemulapalli, Ramesh. / Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51. In: Clinical and Diagnostic Laboratory Immunology. 2005 ; Vol. 12, No. 12. pp. 1429-1436.
@article{f2c645483c414fa2a66f4b4b872f5c2c,
title = "Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51",
abstract = "Brucella abortus strain RB51 is an attenuated rough mutant used as the live vaccine against bovine brucellosis in the United States and other countries. We previously reported the development of strain RB51 as a bacterial vaccine vector for inducing Th1-type immune responses against heterologous proteins. Because safety concerns may preclude the use of strain RB51-based recombinant live vaccines, we explored the ability of a gamma-irradiated recombinant RB51 strain to induce heterologous antigen-specific immune responses in BALB/c mice. Exposure of strain RB51G/LacZ expressing Escherichia coli β-galactosidase to a minimum of 300 kilorads of gamma radiation resulted in complete loss of replicative ability. These bacteria, however, remained metabolically active and continued to synthesize β-galactosidase. A single intraperitoneal inoculation of mice with 109 CFU equivalents of gamma-irradiated, but not heat-killed, RB51G/LacZ induced a β-galactosidase-specific Th1-type immune response. Though no obvious differences were detected in immune responses to B. abortus-specific antigens, mice vaccinated with gamma-irradiated, but not heat-killed, RB51G/LacZ developed significant protection against challenge with virulent B. abortus. In vitro experiments indicated that gamma-irradiated and heat-killed RB51G/LacZ induced maturation of dendritic cells; however, stimulation with gamma-irradiated bacteria resulted in more interleukin-12 secretion. These results suggest that recombinant RB51 strains exposed to an appropriate minimum dose of gamma radiation are unable to replicate but retain their ability to stimulate Th1 immune responses against the heterologous antigens and confer protection against B. abortus challenge in mice.",
author = "Neelima Sanakkayala and Anna Sokolovska and Jatinder Gulani and Harm HogenEsch and Nammalwar Sriranganathan and Boyle, {Stephen M.} and Schurig, {Gerhardt G.} and Ramesh Vemulapalli",
year = "2005",
month = "12",
doi = "10.1128/CDLI.12.12.1429-1436.2005",
language = "English (US)",
volume = "12",
pages = "1429--1436",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51

AU - Sanakkayala, Neelima

AU - Sokolovska, Anna

AU - Gulani, Jatinder

AU - HogenEsch, Harm

AU - Sriranganathan, Nammalwar

AU - Boyle, Stephen M.

AU - Schurig, Gerhardt G.

AU - Vemulapalli, Ramesh

PY - 2005/12

Y1 - 2005/12

N2 - Brucella abortus strain RB51 is an attenuated rough mutant used as the live vaccine against bovine brucellosis in the United States and other countries. We previously reported the development of strain RB51 as a bacterial vaccine vector for inducing Th1-type immune responses against heterologous proteins. Because safety concerns may preclude the use of strain RB51-based recombinant live vaccines, we explored the ability of a gamma-irradiated recombinant RB51 strain to induce heterologous antigen-specific immune responses in BALB/c mice. Exposure of strain RB51G/LacZ expressing Escherichia coli β-galactosidase to a minimum of 300 kilorads of gamma radiation resulted in complete loss of replicative ability. These bacteria, however, remained metabolically active and continued to synthesize β-galactosidase. A single intraperitoneal inoculation of mice with 109 CFU equivalents of gamma-irradiated, but not heat-killed, RB51G/LacZ induced a β-galactosidase-specific Th1-type immune response. Though no obvious differences were detected in immune responses to B. abortus-specific antigens, mice vaccinated with gamma-irradiated, but not heat-killed, RB51G/LacZ developed significant protection against challenge with virulent B. abortus. In vitro experiments indicated that gamma-irradiated and heat-killed RB51G/LacZ induced maturation of dendritic cells; however, stimulation with gamma-irradiated bacteria resulted in more interleukin-12 secretion. These results suggest that recombinant RB51 strains exposed to an appropriate minimum dose of gamma radiation are unable to replicate but retain their ability to stimulate Th1 immune responses against the heterologous antigens and confer protection against B. abortus challenge in mice.

AB - Brucella abortus strain RB51 is an attenuated rough mutant used as the live vaccine against bovine brucellosis in the United States and other countries. We previously reported the development of strain RB51 as a bacterial vaccine vector for inducing Th1-type immune responses against heterologous proteins. Because safety concerns may preclude the use of strain RB51-based recombinant live vaccines, we explored the ability of a gamma-irradiated recombinant RB51 strain to induce heterologous antigen-specific immune responses in BALB/c mice. Exposure of strain RB51G/LacZ expressing Escherichia coli β-galactosidase to a minimum of 300 kilorads of gamma radiation resulted in complete loss of replicative ability. These bacteria, however, remained metabolically active and continued to synthesize β-galactosidase. A single intraperitoneal inoculation of mice with 109 CFU equivalents of gamma-irradiated, but not heat-killed, RB51G/LacZ induced a β-galactosidase-specific Th1-type immune response. Though no obvious differences were detected in immune responses to B. abortus-specific antigens, mice vaccinated with gamma-irradiated, but not heat-killed, RB51G/LacZ developed significant protection against challenge with virulent B. abortus. In vitro experiments indicated that gamma-irradiated and heat-killed RB51G/LacZ induced maturation of dendritic cells; however, stimulation with gamma-irradiated bacteria resulted in more interleukin-12 secretion. These results suggest that recombinant RB51 strains exposed to an appropriate minimum dose of gamma radiation are unable to replicate but retain their ability to stimulate Th1 immune responses against the heterologous antigens and confer protection against B. abortus challenge in mice.

UR - http://www.scopus.com/inward/record.url?scp=29144475473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144475473&partnerID=8YFLogxK

U2 - 10.1128/CDLI.12.12.1429-1436.2005

DO - 10.1128/CDLI.12.12.1429-1436.2005

M3 - Article

C2 - 16339067

AN - SCOPUS:29144475473

VL - 12

SP - 1429

EP - 1436

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 12

ER -